Replies to post #20536 on Humanigen Inc (fka HGENQ)

[Knuckle Sandwich]

Nice job! That $25 - $31 range is such a modest target based on potential here but just goes to prove how undervalued the company is still. Once HGEN is sitting at 25 - 30 more proof will be on the table and price could rocket North from there. They will have to grind to earn every penny to get to $25 - $30 but sky is the limit after its established.

[Knuckle Sandwich]

Below are the 4 remaining Analysts from September's Pre-Nasdaq Investor Call that have not yet initiated coverage. I think that all 4 might have something to say here.

1. Jim Birchenough with Wells Fargo

2. Madhu Kumar with Robert W. Baird

3. Kevin DeGeeter with Oppenheimer

4. Benjamin Burnett with Stifel Nicolaus


Plus the 4 from Jdc1's latest email that participated and have since initiated coverage so far:

Anthony Butler Roth Capital: October 1st 2020 - $25 price target
Joseph Pantginis H.C. Wainwright: October 14th 2020 - 31$ Price target
Louise Chen- Cantor Fitzgerald: October 21st 2020- $25 Price Target
Olga Smolentseva Bryan Garnier: October 22nd 2020 - $30 Price Target

Analyst Average of $27.75 represents a Market Cap of $1.4 Billion

HGEN is also participating in the upcoming conferences:

1. Roth Capital on 10/28
2. Bryan, Garnier & Co 11/16 & 11/17
3. Stifel on 11/17
4. Jefferies on 11/19


Phase III is near completion, EUA is on Tap and Company has already had a Type B Meeting with FDA in regarding submission plan for EUA & BLA.

NIH Sponsored "Big Effect Trail" ACTIV-5 is underway and already recruiting thru Emory University. This is a Double-blind, placebo-controlled study of 200 patients, NIH-sponsored, up to 40 US sites with Interim analysis planned at 50% enrollment. This should move very quickly.


Phew, HGEN has allot of things happening right now!